Skip navigation links
3M
Albaraka Turk
Alstom
Avanti
BASF
BNP Paribas
Bosch
Cargill
Citibank
Coca-Cola
Delivery Hero
DHL
Ericsson
Ford
GE
Huawei
Hyundai
ICBC
Intel
Kuveyt Turk
MAN
MANGO
Microsoft
Nestlé
Novartis
Pfizer
Pirelli
Schneider Electric
Shell
Siemens
Toyota
UniCredit
Unilever
UPS
This page is print preview page.
Click here to return to the page.
Print page

Novartis 

 

Novartis is a global healthcare company based in Basel, Switzerland, whose mission is to use science-based innovation to address some of society’s most challenging healthcare issues. In 2016, Novartis products reached nearly 1 billion people across more than 180 countries. The Novartis Group operates primarily through three divisions that each have a global scale. These divisions are innovative medicines, eye care (Alcon), and generic medicines (Sandoz).

 

The Novartis global portfolio of innovative patented medicines includes more than 50 key marketed products, many of which are amongst the leaders in their therapeutic areas. The Novartis Pharmaceuticals portfolio addresses a wide range of therapeutic areas, including cardiovascular-metabolic, ophthalmology, respiratory, neuroscience, immunology, and dermatology. Novartis Oncology is a leader in driving the practice of precision oncology treatment.

 

Sandoz is a global leader in generic pharmaceuticals and biosimilars. Sandoz pioneers novel approaches to help people around the world access high-quality medicines. It has a portfolio of more than 1,000 products covering all major therapeutic areas.

 

Alcon provides innovative products that enhance quality of life by helping people worldwide see better. Its Surgical and Vision Care businesses offer a wide spectrum of eye care products.

 

Globally, Novartis invested USD 8.9 billion in R&D for new drugs and medical devices in 2015. With an R&D success rate three times higher than the industry average, Novartis is consistently seen as having one of the industry’s most respected development pipelines. As of January 2016, there are more than 200 projects in clinical development.

 

Novartis has been committed to Turkey for more than 60 years. Today, the Novartis Group has four manufacturing sites in Turkey, producing key products as well as several globally-exported products. The Group employs more than 2,300 qualified people and has assumed the leading role in the sector with its understanding of creating a people-oriented company culture and the best working place for its employees.

 

In 2015, Novartis Turkey’s total export was USD 140 million. Over the last decade, its exports have exceeded USD 1 billion in total. So far, Novartis has invested over USD 225 million in its four Turkish sites. The facility in Kurtköy, Istanbul, is one of 10 global centers of excellence at Novartis. In 2015, the Kurtköy plant was designated as the main manufacturing center for the anti-malaria drug manufactured for the “Malaria Initiative.” The Malaria Initiative is one of the pharmaceutical industry's largest access-to-medicines programs and it is focused on treatment, access, capacity-building, and R&D. This production transfer shows the Novartis commitment to Turkey as a center for pharmaceutical investments. The drug is being exported across the world, to more than 50 malaria endemic countries. The Kurtköy plant is front and center in the global fight against malaria, with an annual output capacity of 100 million treatments.

 

The Novartis Group is also the leading pharma company in clinical research in Turkey, accounting for 20 percent of all clinical trial investments by multinational corporations in Turkey. In 2015, the overall clinical trial investments were USD 25 million. In the last six years, Novartis Turkey has invested more than USD 100 million in clinical trials in Turkey, helping make Turkish doctors globally more competitive in research.

 

Novartis focuses on scientific innovations that will result in new ways to improve and extend people’s lives. It is only by hearing from people affected by a disease that one can truly understand their needs. This is why Novartis engages with patients, caregivers, patient organizations, and patient communities to listen and learn about their experiences, recognize their needs, and understand what is meaningful for them. By acting on these unique insights, Novartis will continue to develop and deliver innovative and relevant medicines faster and more efficiently to patients and society.

 

The long-term goal of Novartis Turkey is to continue growing with Turkey and to assume a pioneering role in further advancing the local pharmaceutical industry with more investment, more R&D, and more output.